Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
Status:
Terminated
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving gefitinib before surgery may shrink the tumor so that it can
be removed.
PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with
stage I, stage II, or stage III esophageal cancer that can be removed by surgery.